FENNEC PHARMACEUTICALS INC. Logo

FENNEC PHARMACEUTICALS INC.

Prevents chemotherapy-induced hearing loss in children with its sole product, PEDMARK®.

FENC | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
PO BOX 13628, 27709 RESEARCH TRIANGLE PARK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Fennec Pharmaceuticals Inc. is a commercial-stage specialty biopharmaceutical company focused on the development and commercialization of its sole product, PEDMARK®. PEDMARK®, a unique formulation of sodium thiosulfate, is designed to prevent ototoxicity (hearing loss) in pediatric patients who are receiving platinum-based chemotherapy, such as cisplatin. The company is dedicated to addressing this specific unmet medical need to improve the quality of life for children undergoing cancer treatment by mitigating the long-term, debilitating side effects of chemotherapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all FENNEC PHARMACEUTICALS INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for FENNEC PHARMACEUTICALS INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for FENNEC PHARMACEUTICALS INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Atara Biotherapeutics, Inc. Logo
Pioneering off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.
United States of America ATRA
Atea Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing oral antiviral therapies for viruses like Hepatitis C.
United States of America AVIR
Athira Pharma, Inc. Logo
Developing small-molecule therapies to slow neurodegeneration in diseases like Alzheimer's.
United States of America ATHA
ATOSSA THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing (Z)-endoxifen for breast cancer treatment and prevention.
United States of America ATOS
Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.
South Korea 355690
aTYR PHARMA INC Logo
Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.
United States of America ATYR
Aura Biosciences, Inc. Logo
Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.
United States of America AURA
Aurinia Pharmaceuticals Inc. Logo
Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.
United States of America AUPH
AURORA CANNABIS INC Logo
A global producer and seller of medical and recreational cannabis and derivative products.
United States of America ACB
Autolus Therapeutics plc Logo
Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.
United States of America AUTL

Talk to a Data Expert

Have a question? We'll get back to you promptly.